title: Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy.
abstract: OBJECTIVE
  The present study was undertaken to identify the patients suitable for bladder preservation by analysis of our data.
  
  
  METHODS
  The subjects of this study were all 72 patients with T2-3N0M0 bladder cancer who underwent bladder-preserving therapy in our institute. The therapy involved intra-arterial chemotherapy with MTX and CDDP and concomitant radiotherapy.
  
  
  RESULTS
  Of the evaluable 70 cases, complete response (CR) was confirmed in 57 cases (81.4%). Among 56 bladder preserved cases, 47 (83.9%) preserved their functioning bladder, and 9 underwent salvage radical cystectomy at the following period. The median follow-up was 45.3 months. The 5-year cause-specific survival rate was 81% and the 5-year overall survival rate was 66%. On the basis of the results of univariate analysis, variables contributing to CR were selected. In T2, tumor size of </=3 cm was scored 0 and >3 cm was scored 1, whereas single tumor was scored 0 and multiple were scored 1. In T3, tumor size of </=3 cm was scored 0 and >3 cm was scored 1, whereas G2 was scored 0 and G3 scored 1. The CR rates were 93.8, 92.6, and 62.9% for total scores of 0, 1, and 2, respectively (P = 0.003; score 0 or 1 versus 2). The overall survival rate was significantly higher in the former group (P = 0.003).
  
  
  CONCLUSIONS
  Bladder-preserving therapy can be acceptable for cases of single T2N0M0 tumor with a size of </=3 cm and for T3N0M0 cases with a tumor size of </=3 cm.
authors.affiliation: Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba City, Ibaraki 305-8575, Japan. akazah@md.tsukuba.ac.jp.
authors.forename: Naoto
authors.initials: N
authors.lastname: Miyanaga
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Akaza
authors.forename: Shiro
authors.initials: S
authors.lastname: Hinotsu
authors.forename: Akira
authors.initials: A
authors.lastname: Joraku
authors.forename: Takehiro
authors.initials: T
authors.lastname: Oikawa
authors.forename: Noritoshi
authors.initials: N
authors.lastname: Sekido
authors.forename: Koji
authors.initials: K
authors.lastname: Kawai
authors.forename: Toru
authors.initials: T
authors.lastname: Shimazui
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D018570:Risk Assessment; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D008727:Methotrexate